Fig. 2From: Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational studyDisease progression and relapse free at last visit (intention-to-treat population), for whom these data were available (aged 41–50 years, n = 301; aged > 50 years, n = 135)Back to article page